Simulations Plus – Consensus shows potential upwards of 32.9%

Simulations Plus found with ticker (SLP) now have a total of 3 analysts who cover the share. The consensus rating is “Buy”. The target price is between 75 and 53, whereby we calculate the average price of 60.67. With stocks previously closing at 45.65, this now points to a potential upside of 32.9%. The 50-day MA is 47.66 and the 200-day MA is 51.43. The company’s market capitalization is $ 964 million. Further information can be found at: https://www.simulations-plus.com

Simulations Plus develops drug discovery and development software for modeling, simulating and predicting molecular properties using artificial intelligence and machine learning-based technology worldwide. It works in four segments: Simulations Plus, Cognigen, DILIsym and Lixoft. The company offers GastroPlus, which simulates the uptake and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also offers products based on mechanistic and mathematical models such as DILIsym, quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides absorption, distribution, metabolism, excretion and toxicity predictors for chemistry-based computer programs that use molecular structures as inputs and predict their properties; and MedChem Designer as well as modeling and simulation products consisting of MonolixSuite and PKPlus. It also provides contract research services for population modeling and simulation; Providing training and advice to expedite pharmacometric studies; and clinical pharmacological advisory services to support regulatory filings. The company serves pharmaceutical, biotechnology, agrochemical, cosmetic and food companies as well as academic and government agencies. Simulations Plus was founded in 1996 and is headquartered in Lancaster, California.